Protagonist Therapeutics (PTGX) Change in Taxes (2024 - 2025)
Protagonist Therapeutics (PTGX) reported Change in Taxes of -$1.9 million for Q2 2025, down 179.44% on a YoY basis from $2.4 million in Q2 2024, and down 136.12% sequentially from -$800000.0 in Q1 2025.
Protagonist Therapeutics (PTGX) Change in Taxes (2024 - 2025) Analysis & Trends
Protagonist Therapeutics (PTGX) has 2 years of Change in Taxes data on file, last reported at -$1.9 million in Q2 2025.
- For the quarter ending Q2 2025, Change in Taxes fell 179.44% year-over-year to -$1.9 million; the trailing twelve-month figure through Dec 2025 stood at -$2.7 million (down 200.0% YoY), and the FY2025 full-year result was -$2.7 million, down 200.0% from the prior year.
- Change in Taxes retreated to -$1.9 million in Q2 2025, from -$800000.0 in the prior quarter.
- In the past five years, Change in Taxes ranged from a high of $3.3 million in Q1 2024 to a low of -$1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -800,000.00 |
| Mar 31, 2025 | -800,000.00 |
| Dec 31, 2024 | 1.64 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -676,000.00 |
| Jun 30, 2024 | -676,000.00 |
| Mar 31, 2024 | 3.33 Mn |
| Mar 31, 2024 | 3.33 Mn |